Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago.
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment.
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
Enovis (NYSE:ENOV – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and target prices for Enovis and Envoy Medical, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 0 8 0 3.00 Envoy Medical 0 0 2 0 3.00 Enovis presently has a consensus target price of $75.43, indicating a potential upside of 43.92%. Envoy Medical has a consensus target price of $6.00, indicating a potential upside of 92.93%. Given Envoy Medical’s higher possible upside, analysts clearly believe Envoy Medical is more favorable than Enovis. Institutional and Insider Ownership 98.5% of Enovis shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Volatility & Risk Enovis has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Profitability This table compares Enovis and Envoy Medical’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Enovis -4.51% 3.98% 2.88% Envoy Medical N/A N/A -112.11% Valuation and Earnings This table compares Enovis and Envoy Medical’s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $1.71 billion 1.68 -$33.26 million ($1.50) -34.94 Envoy Medical $316,000.00 192.90 -$29.91 million N/A N/A Envoy Medical has lower revenue, but higher earnings than Enovis. Summary Enovis beats Envoy Medical on 6 of the 11 factors compared between the two stocks. About Enovis (Get Free Report) Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. About Envoy Medical (Get Free Report) Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.